Evaluation of an in situ forming hydrogel wound dressing based on oxidized alginate and gelatin.
Wound dressings that can be formed in situ offer several advantages over the use of preformed dressings such as conformability without wrinkling or fluting in the wound bed, ease of application and improved patient compliance and comfort. Here we describe such an in situ forming hydrogel wound dressing from gelatin, oxidized alginate and borax. Periodate oxidized alginate rapidly cross-links proteins such as gelatin in the presence of borax to give in situ forming hydrogels that are both non-toxic and biodegradable. The composite matrix has the haemostatic effect of gelatin, the wound healing-promoting feature of alginate and the antiseptic property of borax to make it a potential wound dressing material. The hydrogel was found to have a fluid uptake of 90% of its weight which would prevent the wound bed from accumulation of exudates. The water vapour transmission rate (WVTR) of the hydrogel was found to be 2686+/-124 g/m2/day indicating that the hydrogel can maintain a moist environment over wound bed in moderate to heavily exuding wound which would enhance epithelial cell migration during the healing process. The wound healing efficacy of hydrogel was evaluated in experimental full thickness wounds using a rat model which demonstrated that within 2 weeks, the wound covered with gel was completely filled with new epithelium without any significant adverse reactions. These in situ forming hydrogels fulfil many critical elements desirable in a wound dressing material.
Balakrishnan
Biji
B
Division of Polymer Chemistry, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Satelmond Palace Campus, Trivandrum, Kerala 695 012, India.
Mohanty
M
M
Umashankar
P R
PR
Jayakrishnan
A
A
D000464:Alginates / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D047070:Bandages, Hydrocolloid; D001672:Biocompatible Materials / Q000032:analysis / Q000737:chemistry; D004867:Equipment Design; D019544:Equipment Failure Analysis; D005780:Gelatin / Q000737:chemistry / Q000627:therapeutic use*; D020723:Glucuronic Acid / Q000737:chemistry / Q000627:therapeutic use; D006603:Hexuronic Acids / Q000737:chemistry / Q000627:therapeutic use; D020100:Hydrogels / Q000737:chemistry / Q000627:therapeutic use; D008297:Male; D008422:Materials Testing; D010084:Oxidation-Reduction; D051381:Rats; D017208:Rats, Wistar; D012867:Skin / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D014951:Wounds, Stab / Q000188:drug therapy* / Q000473:pathology*
D000464:Alginates; D001672:Biocompatible Materials; D006603:Hexuronic Acids; D020100:Hydrogels; D020723:Glucuronic Acid; D005780:Gelatin